@j Checkpoint blockade works in tumours types with mismatch DNA repair defects https://www.science.org/content/article/cancer-immunotherapy-takes-aim-mutation-riddled-tumors
However, most patients don't have such defects. So, one group decided to test temozolomide, which disables mismatch repair genes, to a number of patients with advanced MSS CRC, which usually doesn't respond to checkpoint inhibitor therapy, due to very few mutations. Now, the clinical data from the trial shows proof-of-concept https://ascopubs.org/doi/full/10.1200/JCO.21.02583
Also, unpublished preclinical data showed that adding cisplatin with temozolomide had a synergistic effect and a trial is recruiting https://clinicaltrials.gov/ct2/show/NCT04457284
In addition, one company is working on first-in-class small molecules https://www.neophore.com
@jcancom Hopefully, there will be a combo trial (with an anti-PD-1) in patients with liver mets as they correlate with reduced immunotherapy efficacy (both ORR and OS) https://www.nature.com/articles/s41591-020-1131-x
critic thank you for replying.
My New Year's Resolution is to get back to the forum. I'll start the New Year off right with a post.
I have been wondering about 3-BP's effectiveness in the BRAF resistant form of melanoma; below article found that melanoma in this context is highly metabolic and 3-BP had substantial anti-cancer effects.
https://pubmed.ncbi.nlm.nih.gov/36555289/
I am very excited to see what 2023 will offer us. Finally having the needed clinical evidence for 3-BP could help so many people struggling with metastatic illness.
Best Wishes for 2023!
@jcancom that's a great new year's resolution, J! I always think in terms of combinations, and Rapamycin seems like a good substance to try with 3BP, likely resulting in a reduced dose requirement of 3BP to achieve similar effects.
Best wishes for 2023!
